Biotech News

Scholar Rock Reports Third Quarter 2026 Financial Results and Recent Business Highlights

Scholar Rock (SRRK)Scholar RockEarnings

U.S. launch of ISEMBYLD™ (apitegromab-mstn), the first and only muscle-targeted therapy for children and adults living with spinal muscular atrophy (SMA), underway following September 11, 2026 FDA approval ISEMBYLD shipped to specialty network prior to quarter-end, reflecting Q3 2026 ISEMBYLD

Related news

Scholar Rock

Myostatin Biology Scholar Rock develops therapies that selectively modulate growth factors in their latent forms. Its lead work targets myostatin to improve muscle function while preserving related signaling pathways. Apitegromab Apitegromab is a selective inhibitor of latent myostatin under FDA review for children and adults with spinal...

Recent company news

Stock data

Close
50.37 USD
Market cap
5.35B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States